A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer.

Cumulative survival analyses between the two groups of mice revealed that seven of nine (77.7%) controls and two of eight treated (25%) mice died at T42, thus indicating a clear trend of therapeutic benefit in mime[4]CRM -treated versus control mice in the observed period (long rank test p < 0.083, data not shown).

also in 19,460 other papers

Remarkably, the reduction in the primary tumor growth between the two groups of mice was still visible after 4 weeks of treatment (i.e., after T28), even though it did not reach statistical significance (data not shown).

also in 111,027 other papers